About: Board of Directors

Mark D. Myslinski

Mr. Myslinski brings nearly thirty years of life sciences and diagnostics industry experience to RedPath, including key sales and operating roles in both Fortune 100 and venture-backed start-up organizations. Mr. Myslinski has been a Johnson & Johnson executive since 2002 where his responsibilities have included building a new, world-wide Evidence Based Medicine function for the Ortho-Clinical Diagnostics unit. For five years, Mr. Myslinski was also General Manager of Johnson & Johnson's Veridex, LLC, a division focused on molecular and cellular diagnostics that achieved rapid sales growth under Mr. Myslinski's tenure. Previously, Mr. Myslinski held executive roles in venture-backed start-ups, Interscope Technologies and Precision Therapeutics, both focused on the field of pathology with an emphasis on cancer. Mr. Myslinski also accumulated over twenty years of sales and marketing experience prior to these roles, including over eight years with Baxter/American Hospital Supply Corporation.

Back